Literature DB >> 8372405

CCK in animal and human research on anxiety.

J Harro1, E Vasar, J Bradwejn.   

Abstract

Much data has accumulated over the past decade supporting the hypothesis that CCK plays a role in the neurobiology of anxiety and panic attacks. These data originated from animal studies and human studies that were initiated independently, but the conclusions are remarkably consistent. In this review, Jacques Bradwejn and colleagues examine the evidence for a role of CCK in anxiety and panic attacks, and highlight the consistencies between animal and human studies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8372405     DOI: 10.1016/0165-6147(93)90020-k

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  31 in total

1.  Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat.

Authors:  P W Frankland; S A Josselyn; J Bradwejn; F J Vaccarino; J S Yeomans
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

Review 2.  The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.

Authors:  A J Greenshaw; P H Silverstone
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

3.  Cholecystokinin peptides and receptor binding in Alzheimer's disease.

Authors:  C Löfberg; J Harro; C G Gottfries; L Oreland
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Targeted invalidation of CCK2 receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test.

Authors:  Sirli Raud; Jürgen Innos; Urho Abramov; Ain Reimets; Sulev Kõks; Andres Soosaar; Toshimitsu Matsui; Eero Vasar
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

5.  Targeted mutation of CCK2 receptor gene modifies the behavioural effects of diazepam in female mice.

Authors:  Sirli Raud; Kertu Rünkorg; Alar Veraksits; Ain Reimets; Aleksei Nelovkov; Urho Abramov; Toshimitsu Matsui; Michel Bourin; Vallo Volke; Sulev Kõks; Eero Vasar
Journal:  Psychopharmacology (Berl)       Date:  2003-04-23       Impact factor: 4.530

6.  Increased cholecystokinin labeling in the hippocampus of a mouse model of epilepsy maps to spines and glutamatergic terminals.

Authors:  M S Wyeth; N Zhang; C R Houser
Journal:  Neuroscience       Date:  2011-12-03       Impact factor: 3.590

Review 7.  The production and role of gastrin-17 and gastrin-17-gly in gastrointestinal cancers.

Authors:  Jeffrey Copps; Richard F Murphy; Sándor Lovas
Journal:  Protein Pept Lett       Date:  2009       Impact factor: 1.890

8.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

9.  Cholecystokinin peptides and receptors in the rat brain during stress.

Authors:  J Harro; C Löfberg; J F Rehfeld; L Oreland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-06       Impact factor: 3.000

10.  Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram.

Authors:  Innar Tõru; Jakov Shlik; Eduard Maron; Veiko Vasar; David J Nutt
Journal:  Psychopharmacology (Berl)       Date:  2006-03-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.